Cargando…
ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma
BACKGROUND: Immunocheckpoint inhibitors (ICIs) have been widely used in the clinical treatment of lung cancer. Although clinical studies and trials have shown that patients can benefit significantly after PD-1/PD-L1 blocking therapy, less than 20% of patients can benefit from ICIs therapy due to tum...
Autores principales: | Qu, Tongyuan, Zhang, Wenshuai, Yan, Chenhui, Ren, Danyang, Wang, Yalei, Guo, Yuhong, Guo, Qianru, Wang, Jinpeng, Liu, Liren, Han, Lei, Li, Lingmei, Huang, Qiujuan, Cao, Lu, Ye, Zhaoxiang, Zhang, Bin, Zhao, Qiang, Cao, Wenfeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204161/ https://www.ncbi.nlm.nih.gov/pubmed/37217923 http://dx.doi.org/10.1186/s12967-023-04135-1 |
Ejemplares similares
-
ISG15 induces ESRP1 to inhibit lung adenocarcinoma progression
por: Qu, Tongyuan, et al.
Publicado: (2020) -
A nomogram-based immune-serum scoring system predicts overall survival in patients with lung adenocarcinoma
por: Huang, Qiujuan, et al.
Publicado: (2021) -
Multidisciplinary team for the diagnosis and treatment of 2 cases of primary intestinal yolk sac tumor
por: Huang, Qiujuan, et al.
Publicado: (2018) -
Bioinformatic Analysis of The Prognostic Value of A Panel of
Six Amino Acid Transporters in Human Cancers
por: Liu, Yaqi, et al.
Publicado: (2023) -
Transforming growth factor-β1 induces EMT by the transactivation of epidermal growth factor signaling through HA/CD44 in lung and breast cancer cells
por: LI, LINGMEI, et al.
Publicado: (2015)